| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 2 interim results example | Phase 2 | — | Subscribe to access the data. | Antibody-Drug Conjugates (ADCs) | Oncology | ||
Phase 2 interim results example | Phase 2 | — | Subscribe to access the data. | Antibody-Drug Conjugates (ADCs) | Oncology | ||
Phase 2 interim results example | Phase 2 | — | Subscribe to access the data. | Antibody-Drug Conjugates (ADCs) | Oncology |
Recent Updates
Recently added Catalysts
Kyntra Bio, Inc.$7.39
+0.18 (+2.5%)
B 69Pipeline Score Undervalued Pharma · Clinical
Market Cap
28.30 M
EPS
27.47
P/E Ratio
0.25 $
Value Trade
39.79 K
SEC Financials
Q1 2026Dilution Risk
25%Revenue
3.74 M
R&D Expenses
7.57 M
Operating CF
-13.89 M
Total Assets
109.63 M
Total Liabilities
118.92 M
Equity
-43.80 M
D/E Ratio
12,345
0.63 %
Week
-3.19 %
1 Month
-12.52 %
3 Month
-15.88 %
6 Month
-99.95 %
5 Year
-99.95 %
All Time
Cash Data
Cash Position
87.24 M
Monthly Burn
4.63 M
Runway
16.8 mo
Burn Trend
SEC Filing
May 12, 2026
Overview
Volume
10.23 K
52 Week Range
4.85 - 208.63
% held by Insiders
2.31 %
% held by Institutions
25.59 %
Enterprise Value
-5.18 M
Total Shares
4.05 M
Short %
2.77 %
Float Shares
3.88 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Kyntra Bio, Inc.
372Total events
3Upcoming
141Tier-1 (high impact)
2015 – 2028Coverage
Upcoming catalysts 2
TBD
T1Interim Analysis
Subscribe to view catalyst details
TBD
T2Runway Guidance Update
Subscribe to view catalyst details
Event history 2
TBD
◆Trial InitiationroxadustatApprovedTrial
Subscribe to view catalyst details
TBD
◆Poster PresentationroxadustatApprovedPresentation
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
B69
Pipeline Score $425M
Pipeline ValueUndervalued
Valuation Signal9
Drugs Scored15.0x
rNPV / MCap Top 94%
Micro Cap (rank 56 of 912)
Percentile RankKyntra Bio, Inc. holds a solid B-grade pipeline (69/100), with $25.8B risk-adjusted pipeline value, led by roxadustat in Peritoneal Dialysis Chronic Kidney Disease Patients With Anemia (Phase 3).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| roxadustat Small molecule | Peritoneal Dialysis Chronic Kidney Disease Patients With Anemia | Phase 3 | NCT02780726 | 85% | $21.1B | COMPLETED | 56 | - | - | Aug 2, 2017 | - | Oct 30, 2024 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
roxadustat Orphan | anemia due to lower-risk myelodysplastic syndromes | Phase 3 | 2026-06-11 | 48% vs. 33%; p=0.22; 48% of RS-patients vs. 28% for placebo | Kyntra Bio Presents New Roxadustat Data on Improvements in Transfusion Independence Regardless of Ring Sideroblast Status in Patients with Anemia due to Lower-Risk Myelodysplastic Syndromes Read More | |
roxadustat Orphan | anemia due to lower-risk myelodysplastic syndromes | Phase 3 | 2026-06-11 | 48% vs. 33%; p=0.22; 48% of RS-patients vs. 28% for placebo | Kyntra Bio Presents New Roxadustat Data on Improvements in Transfusion Independence Regardless of Ring Sideroblast Status in Patients with Anemia due to Lower-Risk Myelodysplastic Syndromes Read More | |
roxadustat Orphan | anemia due to lower-risk myelodysplastic syndromes | Phase 3 | 2026-06-11 | 48% vs. 33%; p=0.22; 48% of RS-patients vs. 28% for placebo | Kyntra Bio Presents New Roxadustat Data on Improvements in Transfusion Independence Regardless of Ring Sideroblast Status in Patients with Anemia due to Lower-Risk Myelodysplastic Syndromes Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in KYNB
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
KYNB Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2027-01-15 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2027-01-15 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2027-01-15 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
KYNB▲ +5.5%on this news
Kyntra Bio Presents New Roxadustat Data on Improvements in Transfusion Independence Regardless of Ring Sideroblast Status in Patients with Anemia due to Lower-Risk Myelodysplastic Syndromes
Kyntra Bio presented new data from the Phase 3 MATTERHORN trial, demonstrating that roxadustat significantly improves transfusion independence in patients with lower-risk myelodysplastic syndromes (LR-MDS), regardless of ring sideroblast status. The findings will be showcased at the upcoming European Hematology Association Congress. The pivotal Phase 3 trial protocol is being finalized based on FDA feedback.
Read more →KYNBKyntra Bio Reports First Quarter 2026 Financial Results and Provides Business Update
Kyntra Bio reported its first quarter 2026 financial results, highlighting progress in its clinical pipeline. The Phase 2 trial of FG-3246 for metastatic castration-resistant prostate cancer is advancing, with interim analysis expected in late 2026. Additionally, the company is finalizing the Phase 3 trial protocol for roxadustat based on FDA feedback. Financially, Kyntra has a robust cash position, ensuring operations through 2028.
Read more →KYNBKyntra Bio to Report First Quarter 2026 Financial Results
Kyntra Bio, Inc. will announce its first quarter 2026 financial results on May 11, 2026, after market close. Following the announcement, the management team will host a conference call and webcast to discuss the results and provide a business update. The company is focused on developing therapies for oncology and rare diseases, with ongoing trials for its drugs.
Read more →KYNB▲ +5.5%on this news
Kyntra Bio to Present at the 25th Annual Needham Virtual Healthcare Conference
Kyntra Bio will present at the 25th Annual Needham Virtual Healthcare Conference from April 13-16, 2026. CEO Thane Wettig is scheduled to deliver a presentation on April 13 at 1:30 PM EDT. The management team will also be available for one-on-one meetings with investors. A replay of the presentation will be accessible on the company's website for 90 days.
Read more →KYNBKyntra Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Kyntra Bio reported its fourth quarter and full year 2025 financial results, highlighting the ongoing Phase 2 trial of FG-3246 for metastatic castration-resistant prostate cancer, which is on schedule for interim analysis in late 2026. The company also submitted a Phase 3 trial protocol for roxadustat for anemia in lower-risk myelodysplastic syndromes. Financially, Kyntra Bio reported a net loss of $14.6 million for Q4 2025, with total revenue declining compared to the previous year. The company maintains a robust cash position, expected to sustain operations until 2028.
Read more →KYNB▲ +7.3%on this news
Kyntra Bio to Report Fourth Quarter and Full Year 2025 Financial Results
Kyntra Bio will report its fourth quarter and full year 2025 financial results on March 16, 2026. The company will host a conference call at 5:00 PM ET to discuss these results and provide updates on its corporate performance. Kyntra Bio is known for its development of therapies for oncology and rare diseases, including roxadustat and FG-3246.
Read more →KYNB▼ -9.6%on this news
Kyntra Bio Announces Positive Data from the Investigator-Sponsored Phase 1b/2 Study of FG-3246 in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer to Be Presented at ASCO GU 2026
Kyntra Bio announced positive preliminary data from a Phase 1b/2 study of FG-3246 combined with enzalutamide for metastatic castration-resistant prostate cancer. The study showed a median radiographic progression-free survival of 10.1 months in patients with one prior ARPI. The results will be presented at the ASCO GU 2026 symposium, highlighting the potential of FG-3180 as a biomarker.
Read more →KYNB▲ +6.3%on this news
Kyntra Bio to Participate in Upcoming Investor Conferences - February 17, 2026
Kyntra Bio (KYNB) has announced its participation in two upcoming investor conferences, including the Oppenheimer 36th Annual Healthcare Life Sciences Conference and the Leerink Global Healthcare Conference. The management team will also be available for one-on-one meetings during these events. Kyntra Bio is focused on developing novel therapies, including ongoing trials for roxadustat and FG-3246.
Read more →KYNBdescribed in Kyntra Bio's most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q, each as filed with the Securities and Exchange Commission (SEC), including the risk factors set forth therein. Investors
FibroGen has officially rebranded as Kyntra Bio, effective January 8, 2026, emphasizing its focus on oncology and rare disease therapies. Key highlights include extending its cash runway into 2028, receiving Orphan Drug Designation for its treatment of myelodysplastic syndromes, and ongoing clinical trials for its CD46 targeting ADC and PET imaging agent. The company is also refreshing its corporate branding to align with its strategic direction moving forward. This transformation represents the culmination of significant changes within the company during the past year.
Read more →KYNBFibroGen Reports Third Quarter 2025 Financial Results and Provides Business Update • Completed the sale of FibroGen China to AstraZeneca for approximately $220 million • Initiated the Phase 2 monotherapy tr
FibroGen reported its financial results for Q3 2025, highlighting a successful sale of its Chinese operations to AstraZeneca for $220 million. The company has initiated a Phase 2 trial for FG-3246, targeting metastatic castration-resistant prostate cancer, and reached an agreement with the FDA on key elements for a Phase 3 trial of roxadustat. Financially, FibroGen maintained a cash runway into 2028, although it recorded a net loss of $13.1 million for the quarter and relatively low revenue from continuing operations.
Read more →KYNBFibroGen Completes Sale of FibroGen China to AstraZeneca for Approximately $220 Million • Total consideration for the sale of FibroGen China to AstraZeneca is approximately $220 million, a $60 million increase fro
FibroGen has successfully completed the sale of its subsidiary in China to AstraZeneca for approximately $220 million, marking a significant boost to its financial position. The transaction involved $85 million in enterprise value and $135 million in net cash. The company plans to use the proceeds to extend its cash runway into 2028 and is on track to initiate a Phase 2 trial for FG-3246 in metastatic castration-resistant prostate cancer. Additionally, FibroGen is preparing to file a Phase 3 protocol for roxadustat in treating anemia in patients with lower-risk myelodysplastic syndromes in late 2025.
Read more →KYNBFibroGen Announces Approval of Sale of FibroGen China to AstraZeneca by the China State Administration for Market Regulation • Sale of FibroGen China remains on track to close in 3Q 2025
FibroGen, Inc. announced that the China State Administration for Market Regulation has approved the sale of FibroGen International (Hong Kong) Ltd. to AstraZeneca Treasury Limited. The transaction is part of a prior agreement signed on February 20, 2025, and is expected to close in the third quarter of 2025, pending final conditions. FibroGen remains focused on advancing its therapies for cancer and anemia, including ongoing evaluations for its drugs in various indications.
Read more →KYNBFibroGen Reports Second Quarter 2025 Financial Results and Provides Business Update • Total consideration for the sale of FibroGen China to AstraZeneca now expected to be approximately $210 million, a $50 million
FibroGen, Inc. has announced its financial results for the second quarter of 2025, reporting a total revenue of $1.3 million and a net loss of $13.7 million. The company expects to complete the sale of its subsidiary in China to AstraZeneca for approximately $210 million, which would extend its cash runway into 2028. Additionally, FibroGen is set to commence a Phase 2 trial for FG-3246, a promising treatment for metastatic castration-resistant prostate cancer, and has made significant progress with roxadustat towards a Phase 3 trial for anemia in patients with lower-risk myelodysplastic syndromes. The developments position FibroGen for potential value creation for patients and shareholders.
Read more →KYNBFibroGen Appoints Michael Kauffman, M.D., Ph.D. to its Board of Directors
FibroGen has appointed Dr. Michael Kauffman, an experienced biotech leader, to its Board of Directors as of June 4, 2025. His extensive background in drug development, particularly in oncology, is expected to contribute positively to FibroGen's efforts towards clinical milestones and enhance its pipeline. The company sees this appointment as a strategic move to drive its turnaround strategy. Kauffman's previous leadership roles in notable biotech companies underline his suitable expertise for this position.
Read more →KYNBFibroGen Reports First Quarter 2025 Financial Results and Provides Business Update • Total consideration for the sale of FibroGen China to AstraZeneca now expected to be approximately $185 million, a $25 million i
FibroGen, Inc. has reported its financial results for Q1 2025 and a strategic update. The company has seen a $25 million increase in the anticipated sale value of its subsidiary in China to AstraZeneca, bringing the total to approximately $185 million. Additionally, FibroGen plans to initiate a Phase 2 study for FG-3246, a promising ADC targeting metastatic castration-resistant prostate cancer, expected to start in Q3 2025. The company also filed a Type-C meeting request with the FDA regarding roxadustat for treating anemia associated with lower-risk myelodysplastic syndromes, aiming for feedback in the same quarter.
Read more →KYNBFibroGen Announces Publication of Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer in the Journal of Clinical Oncology • FG-3246 showed encouraging
FibroGen has published results from a Phase 1 monotherapy study of FG-3246, an ADC targeting CD46, in patients with metastatic castration-resistant prostate cancer (mCRPC). The study, published in the Journal of Clinical Oncology, showed promising anti-cancer activity and an acceptable safety profile. Results indicated a confirmed objective response rate of 20% and a disease control rate of 80%. The company plans to initiate Phase 2 trials by mid-2025 to optimize dosing and further explore FG-3246's efficacy, alongside ongoing evaluations with enzalutamide.
Read more →KYNBFibroGen Reports Fourth Quarter and Full Year 2024 Financial Results • Announced sale of FibroGen China to AstraZeneca for a total consideration of approximately $160 million o Transaction expected to close by mid
FibroGen Inc. reported its fourth quarter and full year 2024 financial results, highlighting the sale of FibroGen China to AstraZeneca for about $160 million. The transaction is expected to close by mid-2025, extending the company's cash runway into 2027. FibroGen plans to initiate a Phase 2 trial for its antibody-drug conjugate FG-3246 in mid-2025, while also noting a decrease in revenue for the quarter and the year, along with substantial net losses.
Read more →KYNBFibroGen Announces the Sale of FibroGen China to AstraZeneca for Approximately $160 Million • Purchase price represents enterprise value of $85 million plus FibroGen net cash held in China at closing, currently es
FibroGen has announced the sale of its China subsidiary to AstraZeneca for approximately $160 million, which includes an enterprise value of $85 million and an estimated cash reserve of $75 million. This transaction is set to close by mid-2025 and will allow FibroGen to repay its term loan, thus simplifying its capital structure. The deal is expected to extend the company's cash runway into 2027 while allowing it to further develop its oncology assets, including FG-3246 and FG-3180.
Read more →KYNBFibroGen Appoints David DeLucia as Chief Financial Officer
FibroGen has appointed David DeLucia as its new Chief Financial Officer, effective December 16, 2024. DeLucia previously served as Vice President, Head of Corporate Financial Planning and Analysis, Investor Relations, and Treasury at FibroGen. CEO Thane Wettig highlighted DeLucia's deep understanding of the business and extensive financial leadership experience as key assets for advancing the company's strategic goals in cancer-related therapies. The transition in leadership comes as FibroGen continues to develop innovative treatments targeting CD46 and expanding its existing product portfolio.
Read more →KYNBFibroGen Reports Third Quarter 2024 Financial Results • Topline results from Phase 2 portion of the investigator-sponsored study of FG-3246, a first-in-class antibody-drug conjugate (ADC) targeting CD46, in combin
FibroGen, Inc. reported its financial results for the third quarter of 2024, highlighting a 15% growth in net revenue driven by robust sales of roxadustat in China. The company is anticipating topline results from the Phase 2 study of FG-3246 in combination with enzalutamide in mCRPC in the first half of 2025 and the initiation of a Phase 2 monotherapy trial in early 2025. Despite some setbacks in recent clinical trials, FibroGen's cost reduction plan is progressing well, and the company has sufficient funds to support operations going into 2026.
Read more →KYNBFibroGen Reports Second Quarter 2024 Financial Results and Provides Business Update • Company implementing significant cost reduction plan in the U.S. due to results in late-stage pamrevlumab pancreatic cancer tri
FibroGen has reported its financial results for Q2 2024, showing a 14% increase in net revenue, largely driven by strong performance of roxadustat in China. The company is implementing a significant cost reduction plan, including a 75% reduction in the U.S. workforce, due to disappointing outcomes from pamrevlumab trials for pancreatic cancer. Despite this, FibroGen is focused on further developing FG-3246 and PET46, with promising preliminary data from ongoing studies. The full-year revenue guidance has been raised, indicating optimism regarding roxadustat's continued success.
Read more →KYNBVirtual KOL Investor Event Series Part II: Review FG-3246 Development Program in Metastatic Castration-Resistant Prostate Cancer Hosted by FibroGen Inc. Wednesday
FibroGen Inc. announced details of its FG-3246 development program for metastatic castration-resistant prostate cancer (mCRPC) during a virtual KOL investor event. FG-3246, an investigational drug, aims to address significant unmet medical needs within this patient population. The company boasts a healthy financial position with $214.7 million in cash available to support operations through 2026. Furthermore, positive revenue growth from Roxadustat and new regulatory submissions could strengthen FibroGen's future market prospects.
Read more →KYNBFibroGen Reports First Quarter 2024 Financial Results • Topline data from the Pancreatic Cancer Action Network (PanCAN) Precision Promise SM Phase 2/3 study in metastatic pancreatic cancer anticipated in mid-2024
FibroGen reported its financial results for Q1 2024, showcasing a 55% growth in total revenue year over year, primarily driven by its roxadustat sales in China. The company expects to release topline data from two significant clinical trials involving pamrevlumab in metastatic pancreatic cancer by mid-2024. Despite the strong revenue growth, FibroGen reported a net loss of $32.9 million, reflecting ongoing financial challenges. The firm's cash position appears robust, with a runway extending into 2026, supporting its developmental strategies.
Read more →KYNBFibroGen Reports Fourth Quarter and Full Year 2023 Financial Results • Topline data from two pivotal pamrevlumab pancreatic cancer trials anticipated in 2Q 2024 • Additional data from Phase 1 monotherapy st
FibroGen reported its financial results for the fourth quarter and full year 2023, showcasing a total net revenue of $147.8 million, reflecting a 5% year-over-year increase. Anticipated milestones include topline data from two pivotal trials of pamrevlumab for pancreatic cancer in 2Q 2024, and additional results from a Phase 1 study of FG-3246 expected in 1Q 2024. The company also regained the rights to roxadustat from AstraZeneca in the U.S. and claims a robust cash position that will support operations through 2026. Despite a quarterly net loss, FibroGen is optimistic about its ongoing projects and financial stability.
Read more →KYNBFibroGen Reports Third Quarter 2023 Financial Results • Topline data from two pivotal pamrevlumab pancreatic cancer trials on track to read out in 1H 2024, including the Pancreatic Cancer Action Network (PanCAN) P
FibroGen reported its third quarter 2023 financial results, demonstrating a significant year-over-year revenue increase of 155% to $40.1 million. The company announced the acceptance of a supplemental new drug application for roxadustat in China aimed at chemotherapy-induced anemia, and strong growth in roxadustat sales continues in that region. Despite positive developments, FibroGen faced challenges with negative results from the Phase 3 study of pamrevlumab for Duchenne muscular dystrophy. The company remains on track to report key data from two pivotal pancreatic cancer trials in the first half of 2024.
Read more →KYNBFibroGen Announces Topline Results from LELANTOS-2, a Phase 3 Clinical Study of Pamrevlumab in Ambulatory Duchenne Muscular Dystrophy – Study did not meet the primary endpoint – – Pamrevlumab was gen
FibroGen announced topline results from the Phase 3 LELANTOS-2 trial of pamrevlumab for Duchenne muscular dystrophy (DMD), stating the study did not meet its primary endpoint. Although pamrevlumab was generally safe and well tolerated, key efficacy measures, including the North Star Ambulatory Assessment total score, failed to show significant improvement over placebo. The company is currently evaluating the totality of data and plans to share further insights at an upcoming medical forum. The failure to meet endpoints raises concerns about the future of pamrevlumab as a treatment option for DMD.
Read more →KYNBFibroGen Reports Second Quarter 2023 Financial Results • Topline data from three late-stage pamrevlumab trials expected through 1H 2024, including the Pancreatic Cancer Action Network (PanCAN) Precision PromiseSM
FibroGen, Inc. reported its second-quarter financial results for 2023, showcasing a net revenue increase largely attributed to strong sales of roxadustat in China. The company plans to release topline data from three key pamrevlumab trials in the first half of 2024. However, FibroGen also faced setbacks, including negative results from several Phase 3 studies and an increased net loss of $87.7 million. The interim CEO expressed optimism about the company's future despite these challenges.
Read more →KYNBFibroGen Announces Leadership Transition Appoints Thane Wettig as Interim Chief Executive Officer Wettig succeeds Enrique Conterno and brings over 30 years of global pharmaceutical leadership
FibroGen has appointed Thane Wettig as Interim Chief Executive Officer following the resignation of Enrique Conterno. Wettig, who has been with FibroGen as Chief Commercial Officer since 2020, brings over 30 years of pharmaceutical leadership experience. He has expressed enthusiasm about advancing the company's pipeline, particularly with pamrevlumab and roxadustat. The change in leadership is expected to provide continuity while focusing on strategic priorities.
Read more →KYNBFibroGen Announces Topline Results from Phase 3 ZEPHYRUS-1 Study of Pamrevlumab for the Treatment of Idiopathic Pulmonary Fibrosis  Study did not meet the primary endpoint  Pamrevlumab was generally safe
FibroGen announced topline results from the Phase 3 ZEPHYRUS-1 trial of pamrevlumab for idiopathic pulmonary fibrosis, which failed to meet its primary endpoint of change in forced vital capacity. The safety profile showed that pamrevlumab was generally safe and well tolerated, with most adverse events being mild or moderate. Due to the results, the company will discontinue the ZEPHYRUS-2 study. FibroGen aims to extend its cash runway and will report on other ongoing studies involving pamrevlumab in different conditions.
Read more →KYNBFibroGen Announces Topline Results from LELANTOS-1 Phase 3 Clinical Study of Pamrevlumab in Non-Ambulatory Patients with Duchenne Muscular Dystrophy – Study did not meet the primary endpoint – Pamrevlumab w
FibroGen announced that its LELANTOS-1 Phase 3 clinical study of pamrevlumab for non-ambulatory patients with Duchenne Muscular Dystrophy did not meet its primary endpoint. Despite the disappointment, the company reported that pamrevlumab was generally safe and well tolerated among participants. Results from a related study, LELANTOS-2, focusing on ambulatory patients are expected in the third quarter of 2023. FibroGen plans to share detailed findings at an upcoming medical conference.
Read more →KYNBFibroGen Announces Positive Topline Results from China Pivotal Phase 3 Clinical Trial of Roxadustat for the Treatment of Chemotherapy Induced Anemia • Met primary endpoint of noninferiority of roxadustat to erythr
FibroGen has reported positive topline results from a Phase 3 clinical trial of roxadustat, demonstrating non-inferiority to erythropoietin alfa in treating chemotherapy-induced anemia. The trial involved 159 patients with non-myeloid malignancies and indicated potential benefits in addressing an unmet medical need in China. The company plans to file a supplemental New Drug Application in China based on these results, which could lead to broadened access for patients. Roxadustat is also under review for similar indications globally, reinforcing its significance in the treatment of anemia associated with cancer therapies.
Read more →KYNBFibroGen Reports First Quarter 2023 Financial Results • Topline Data From Four Phase 3 Trials Expected Through 3Q 2023 • Completed Non-Dilutive Term Loan Financing for up to $150 Million with Morgan Stanley
FibroGen, Inc. announced its financial results for Q1 2023, highlighting a 28% increase in net product revenue from roxadustat sales in China. The company completed enrollment in key Phase 3 clinical trials and secured a $150 million non-dilutive term loan financing, enhancing its financial stability. Upcoming topline data from several Phase 3 studies is expected, although the company reported a decrease in total revenue and a larger net loss compared to the previous year.
Read more →KYNBFibroGen Reports Fourth Quarter and Full Year 2022 Financial Results • Topline Data from Five Pivotal Phase 3 Trials in 2023 • Total Company Revenue $140.7 Million in 2022 • Continued Strong Roxadust
FibroGen, Inc. announced its financial results for the fourth quarter and full year 2022, reporting a total revenue of $140.7 million. The company highlighted the strong growth of Roxadustat in China and its potential in addressing unmet medical needs through ongoing Phase 3 trials. However, despite the positive revenue growth for Roxadustat, FibroGen faced a net loss of $293.7 million for the year, though the company believes it is well-funded through key clinical milestones into the second half of 2024. Upcoming trial data could significantly influence the company’s future trajectory.
Read more →KYNBFibroGen Reports Third Quarter 2022 Financial Results • Continued advancement of pamrevlumab clinical trials – topline data from five pivotal Phase 3 trials beginning in 1H 2023 through mid-2024 • Co
FibroGen Reports Third Quarter 2022 Financial Results -Continued advancement of pamrevlumab clinical trials topline data from five pivotal Phase 3 trials beginning in 1H 2023 through mid-2024 -Completed enrollment of MATTERHORN Phase 3 study of roxadustat in patients with anemi
Read more →KYNBFibroGen Reports Second Quarter 2022 Financial Results • Completed enrollment of LELANTOS-2 Phase 3 study of pamrevlumab in ambulatory patients with Duchenne muscular dystrophy • 2Q 2022 revenue of $29.8 mi
FibroGen Reports Second Quarter 2022 Financial Results -Completed enrollment of LELANTOS-2 Phase 3 study of pamrevlumab in ambulatory patients with Duchenne muscular dystrophy - 2Q 2022 revenue of $29.8 million, growth of 22% vs. 2Q 2021 - Continued significant roxadustat volu
Read more →KYNBFibroGen Reports First Quarter 2022 Financial Results Completed enrollment in ZEPHYRUS-1 Phase 3 study of pamrevlumab in idiopathic pulmonary fibrosis 1Q 2022 revenue of $60.8M, growth of 58% vs. 1Q 2021 Significant roxa
FibroGen Reports First Quarter 2022 Financial Results Completed enrollment in ZEPHYRUS-1 Phase 3 study of pamrevlumab in idiopathic pulmonary fibrosis 1Q 2022 revenue of $60.8M, growth of 58% vs. 1Q 2021 Significant roxadustat volume growth in China in first quarter 2022 offse
Read more →KYNBFibroGen Reports Fourth Quarter and Full Year 2021 Financial Results Completed enrollment in LAPIS Phase 3 study of pamrevlumab in locally advanced unresectable pancreatic cancer Completed enrollment in LELANTOS-1 Phase
FibroGen Reports Fourth Quarter and Full Year 2021 Financial Results Completed enrollment in LAPIS Phase 3 study of pamrevlumab in locally advanced unresectable pancreatic cancer Completed enrollment in LELANTOS-1 Phase 3 study of pamrevlumab in Duchenne muscular dystrophy Tot
Read more →KYNBFibroGen Reports Third Quarter 2021 Financial Results Roxadustat Receives EU approval for Patients with Anemia of CKD, triggering a $120M milestone payment from Astellas Roxadustat net product revenue in China of $13.4 m
FibroGen Reports Third Quarter 2021 Financial Results Roxadustat Receives EU approval for Patients with Anemia of CKD, triggering a $120M milestone payment from Astellas Roxadustat net product revenue in China of $13.4 million, on a US GAAP basis Total roxadustat net sales in
Read more →KYNBAstellas Receives European Commission Approval for First-in-Class EVRENZO TM (roxadustat) for Adult Patients with Symptomatic Anemia of Chronic Kidney Disease Roxadustat is the first orally administered hypoxia-inducible
Astellas Receives European Commission Approval for First-in-Class EVRENZOTM (roxadustat) for Adult Patients with Symptomatic Anemia of Chronic Kidney Disease Roxadustat is the first orally administered hypoxia-inducible factor (HIF) prolyl hydroxylase (PH) inhibitor available fo
Read more →KYNBexpertise in hypoxia-inducible factor (HIF) and connective tissue growth factor (CTGF) biology to advance innovative medicines for the treatment of unmet needs. The Company is currently developing and commercializing rox
FibroGen Announces Retirement of Pat Cotroneo and Appointment of Juan Graham as Chief Financial Officer SAN FRANCISCO, Aug. 16, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) announced the retirement of Pat Cotroneo, Chief Financial Officer, and the appointment of Juan G
Read more →KYNBuncertainties related to the continued progress and timing of our various programs, including the enrollment and results from ongoing and potential future clinical trials, and other matters that are described in our Annu
FibroGen Receives Complete Response Letter from the FDA for Roxadustat for Anemia of Chronic Kidney Disease SAN FRANCISCO, AUGUST 11, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that the U.S. Food and Drug Administration (FDA) has issued a complete res
Read more →KYNBFibroGen Reports Second Quarter 2021 Financial Results Roxadustat net product revenue in China of $13.4 million, on a US GAAP basis. Total roxadustat net sales in China of $52.8 million 1 by FibroGen and the distribution
FibroGen Reports Second Quarter 2021 Financial Results Roxadustat net product revenue in China of $13.4 million, on a US GAAP basis. Total roxadustat net sales in China of $52.8 million1 by FibroGen and the distribution entity jointly owned by FibroGen and AstraZeneca Roxadust
Read more →KYNBEluminex Biosciences Investors/Media: Zhenze John Hu, Ph.D., MPD Business Development John.hu@eluminexbio.com
Eluminex Biosciences Exclusively Licenses FibroGen's Biosynthetic Cornea Technology and Recombinant Collagen III Platform SUZHOU, China and SAN FRANCISCO, CA, July 19, 2021 (GLOBE NEWSWIRE) -- Eluminex Biosciences (Suzhou) Limited (Eluminex), an ophthalmology-focused biotechnolo
Read more →KYNBAstellas Receives Positive CHMP Opinion for EVRENZO TM (roxadustat) for Adult Patients with Symptomatic Anemia of Chronic Kidney Disease TOKYO
Astellas Receives Positive CHMP Opinion for EVRENZOTM (roxadustat) for Adult Patients with Symptomatic Anemia of Chronic Kidney Disease TOKYO, June 25, 2021 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and FibroGen, Inc. (Nasdaq: FGEN,
Read more →KYNBFibroGen and HiFiBiO Announce Transformative Partnership to Advance Next-Generation Therapies for Patients with Cancer and Autoimmune Disease FibroGen Exclusively Licenses HiFiBiO s Galectin-9 Program, and Obtains an Exc
FibroGen and HiFiBiO Announce Transformative Partnership to Advance Next-Generation Therapies for Patients with Cancer and SAN FRANCISCO, CA and CAMBRIDGE, MA, June 17, 2021 (GLOBE NEWSWIRE) FibroGen, Inc. (Nasdaq: FGEN) and HiFiBiO Therapeutics, a private, multinational clini
Read more →KYNBFibroGen Reports First Quarter 2021 Financial Results Roxadustat net product revenue in China of $15.4 million, on a US GAAP basis Total roxadustat net sales in China of $43.5 million 1 by FibroGen and the distribution e
FibroGen Reports First Quarter 2021 Financial Results Roxadustat net product revenue in China of $15.4 million, on a US GAAP basis Total roxadustat net sales in China of $43.5 million1 by FibroGen and the distribution entity jointly owned by FibroGen and AstraZeneca, compared t
Read more →KYNBreliance on these forward-looking statements, which speak only as of the date of this release, and we undertake no obligation to update any forward-looking statement in this press release, except as required by law. Cont
FibroGen Announces FDA Advisory Committee to Review Roxadustat New Drug Application Tentatively Scheduled for July 15, 2021 SAN FRANCISCO, APRIL 6, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) announced that the U.S. Food and Drug Administration (FDA) has informed the
Read more →KYNBMedia: Jennifer Harrington +1.610.574.9196 Jennifer.Harrington@gcihealth.com
FibroGen Provides Additional Information on Roxadustat Company Continues to be Confident in the Benefit / Risk Profile of Roxadustat Company to Host Investor Call Today at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) SAN FRANCISCO - April 6, 2021 - FibroGen, Inc. (Nasdaq: F
Read more →KYNBFibroGen Reports Fourth Quarter and Full Year 2020 Financial Results Strong Fourth Quarter China Roxadustat Net Sales of $29.2 Million and 2020 full-year Net Sales of $72.5 Million FDA to hold Advisory Committee Meeting
FibroGen Reports Fourth Quarter and Full Year 2020 Financial Results SAN FRANCISCO, March 1, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today reported financial results for the fourth quarter and full year 2020 and provided an update on the company's recent developme
Read more →KYNBAnnual Report on Form 10-K for the fiscal year ended
FibroGen Provides Regulatory Update on Roxadustat SAN FRANCISCO, December 18, 2020 (GLOBE NEWSWIRE) - FibroGen, Inc. (Nasdaq: FGEN) today announced that the U.S. Food and Drug Administration (FDA) has extended the review period of the New Drug Application (NDA) for roxadustat fo
Read more →KYNBFibroGen Reports THIRD Quarter 2020 Financial Results - Strong third Quarter China Roxadustat Net Sales of $22.7 million - - Conference Call Today at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time
FibroGen Reports THIRD Quarter 2020 Financial Results - Strong third Quarter China Roxadustat Net Sales of $22.7 million - - Conference Call Today at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time - SAN FRANCISCO, November 5, 2020 - FibroGen, Inc. (NASDAQ:FGEN) reported financi
Read more →KYNBFibroGen Reports SECOND Quarter 2020 Financial Results - Strong Second Quarter China Roxadustat Net Sales of $15.7 million - - Conference Call Today at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time
FibroGen Reports SECOND Quarter 2020 Financial Results - Strong Second Quarter China Roxadustat Net Sales of $15.7 million - - Conference Call Today at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time - August 6, 2020 -- FibroGen, Inc. (NASDAQ: FGEN) reported financial results fo
Read more →KYNBFibroGen, Inc. Media Inquiries: Sara Iacovino 1.703.474.4452 sara.iacovino@gcihealth.com Investors: Michael Tung, M.D. Corporate Strategy / Investor Relations 1.415.978.1434 mtung@fibrogen.com
FibroGen Announces New Appointments to its Board of Directors - Appoints Aoife Brennan, M.B., B.Ch., President and CEO of Synlogic Inc. (NASDAQ:SYBX) - - Appoints Ben Cravatt, Ph.D., Professor and the Norton B. Gilula Chair of Chemical Biology in the Department of Chemistry at
Read more →KYNBFibroGen Reports First Quarter 2020 Financial Results - Roxadustat U.S. NDA review and E.U. MAA filing on track - Conference Call Today at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time
FibroGen Reports First Quarter 2020 Financial Results - Roxadustat U.S. NDA review and E.U. MAA filing on track - Conference Call Today at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time SAN FRANCISCO, May 07, 2020 -- FibroGen, Inc. (NASDAQ: FGEN) today reported financial result
Read more →KYNBMASTER SUPPLY AGREEMENT This Master Supply Agreement (the " Agreement ") is effective as of
MASTER SUPPLY AGREEMENT This Master Supply Agreement (the "Agreement") is effective as of March 2, 2020 (the "Effective Date"), by and among: FibroGen, Inc., a Delaware corporation with offices located at 409 Illinois Street, San Francisco, CA 94158 U.S.A., and its Affiliates (c
Read more →KYNBFibroGen Reports Fourth Quarter and Full Year 2019 Financial Results • Roxadustat NDA submission accepted with PDUFA date of
FibroGen Reports Fourth Quarter and Full Year 2019 Financial Results SAN FRANCISCO, March 2, 2020 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today reported financial results for the fourth quarter and full year of 2019 and provided an update on the company's recent develo
Read more →KYNBFibroGen, Inc. Media Inquiries: Sara Iacovino 1.703.474.4452 sara.iacovino@gcihealth.com Investors: Michael Tung, M.D. Investor Relations 1.415.978.1433 ir@fibrogen.com
FibroGen Announces U.S. FDA Acceptance of New Drug Application for Roxadustat for the Treatment of Anemia of Chronic Kidney Disease SAN FRANCISCO, February 11, 2020 (GLOBAL NEWSWIRE) - FibroGen, Inc. (NASDAQ:FGEN) today announced that the U.S. Food and Drug Administration (FDA)
Read more →KYNBAstellas Submits Supplemental New Drug Application for Approval of Evrenzo (roxadustat) for the Treatment of Anemia Associated with Chronic Kidney Disease in Non-Dialysis Dependent Patients in Japan TOKYO a
Astellas Submits Supplemental New Drug Application for Approval of Evrenzo (roxadustat) for the Treatment of Anemia Associated with Chronic Kidney Disease in Non-Dialysis Dependent Patients in Japan TOKYO and San Francisco, January 30, 2020 - Astellas Pharma Inc. (TSE: 4503, P
Read more →KYNBThis presentation contains "forward-looking" statements that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this presentation, including statements rega
FibroGen, Inc. Corporate Presentation January 2020 Exhibit 99.1 This presentation contains "forward-looking" statements that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this presentation, including statements
Read more →KYNBFIBROGEN SUBMITS NEW DRUG APPLICATION TO THE U.S. FDA FOR ROXADUSTAT IN PATIENTS WITH ANEMIA OF CHRONIC KIDNEY DISEASE New Drug Application supported by positive global Phase 3 efficacy and safety results
FIBROGEN SUBMITS NEW DRUG APPLICATION TO THE U.S. FDA FOR ROXADUSTAT IN PATIENTS WITH ANEMIA OF CHRONIC New Drug Application supported by positive global Phase 3 efficacy and safety results SAN FRANCISCO, CA December 23, 2019 (GLOBAL NEWSWIRE) FibroGen, Inc. (NASDAQ:FGEN), toda
Read more →KYNBZhang L, Wang F, Wang L, et al. Prevalence of chronic kidney disease in China: a cross-sectional survey. Lancet 2012; 379:815-22. 4. Collins AJ, Ma JZ, Xia A, Ebben J. Trends in anemia treatment with erythropoietin usage
FibroGen Announces Roxadustat Inclusion in China's National Reimbursement Drug List SAN FRANCISCO, December 2, 2019 -- FibroGen, Inc. (NASDAQ: FGEN) today reported roxadustat has been included on the updated National Reimbursement Drug List (NRDL) released by China's National He
Read more →KYNBFibroGen Reports Third Quarter 2019 Financial Results - Roxadustat Positive Pooled Phase 3 Efficacy and Cardiovascular Safety Data Presented Last Friday at American Society of Nephrology 2019 Kidney Week - Plan to Submit
FibroGen Reports Third Quarter 2019 Financial Results Conference Call Today at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time SAN FRANCISCO, Nov. 11, 2019 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today reported financial results for the third quarter of 2019 and provide
Read more →KYNBAbout FibroGen FibroGen, Inc., headquartered in San Francisco, California, with subsidiary offices in Beijing and Shanghai, People's Republic of China, is a leading biopharmaceutical company discovering and developing a
FibroGen Presents Phase 3 Efficacy and Safety Results for Roxadustat Versus Epoetin Alfa as Treatment of Anemia in Incident Dialysis Patients with Chronic Kidney Disease Roxadustat met both primary efficacy endpoints of mean hemoglobin (Hb) change from baseline and proportion of
Read more →KYNBpredict," "potential," "continue" and similar words, although some forward-looking statements are expressed differently. Our actual results may differ materially from those indicated in these forward-looking statements d
FibroGen Announces Positive Phase 3 Pooled Roxadustat Safety and Efficacy Results for Treatment of Anemia in Chronic Kidney Disease Roxadustat cardiovascular safety comparable to placebo in non-dialysis dependent (NDD) patients, as assessed by Major Adverse Cardiovascular Events
Read more →KYNBThis release contains forward-looking statements regarding our strategy, future plans and prospects, including statements regarding the development of roxadustat, our interpretation of the pooled safety analyses and othe
Roxadustat Global Phase 3 Results for Treatment of Chronic Kidney Disease (CKD) Anemia to be Presented at American Society of Nephrology Kidney Week 2019 Pooled efficacy and cardiovascular safety of roxadustat, compared to epoetin alfa (EPO) in CKD patients on dialysis and comp
Read more →KYNBFibroGen Announces Initiation of Phase 2 Clinical Trial of Roxadustat for the Treatment of Anemia in Cancer Patients Receiving Chemotherapy
FibroGen Announces Initiation of Phase 2 Clinical Trial of Roxadustat for the Treatment of Anemia in Cancer Patients Receiving Chemotherapy SAN FRANCISCO, CA September 26, 2019 FibroGen, Inc. (NASDAQ: FGEN) today announced first patient dosed in the company s Phase 2 clinical
Read more →KYNBRoxadustat Approved in Japan for the Treatment of Anemia Associated with Chronic Kidney Disease in Dialysis Patients SAN FRANCISCO and Tokyo
Roxadustat Approved in Japan for the Treatment of Anemia Associated with Chronic Kidney Disease in Dialysis Patients SAN FRANCISCO and Tokyo, September 20, 2019- FibroGen, Inc. (Nasdaq: FGEN, Interim CEO: James A. Schoeneck, "FibroGen") and Astellas Pharma Inc. (TSE: 4503, Presi
Read more →KYNBFibroGen, Inc. Karen L. Bergman Vice President, Investor Relations and Corporate Communications 1.415.978.1433 ir@fibrogen.com
FIBROGEN ANNOUNCES PASSING OF CEO THOMAS B. NEFF, SCIENTIFIC INNOVATOR AND PIONEERING BIOPHARMACEUTICAL EXECUTIVE SAN FRANCISCO, August 26, 2019 -- FibroGen, Inc. (NASDAQ:FGEN) announced today that Thomas B. Neff, Chief Executive Officer and Chairman of the Board of Directors o
Read more →KYNBROXADUSTAT
ROXADUSTAT APPROVED IN CHINA FOR TREATMENT OF ANEMIA IN CHRONIC KIDNEY DISEASE PATIENTS NOT RECEIVING DIALYSIS SAN FRANCISCO, August 21, 2019 -- FibroGen, Inc. (NASDAQ:FGEN) today announced that the National Medical Products Administration (NMPA) in China has approved expansion
Read more →KYNBFIBROGEN REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS - On Track to Submit U.S. NDA for Roxadustat in October - - Initiated ZEPHYRUS Phase 3 Study of Pamrevlumab in IPF - Conference Call Today at 5:00 p.m. Eastern Time/
FIBROGEN REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS - On Track to Submit U.S. NDA for Roxadustat in October - - Initiated ZEPHYRUS Phase 3 Study of Pamrevlumab in IPF - Conference Call Today at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time SAN FRANCISCO, August 8, 2019 --
Read more →KYNBForward-Looking Statements This release contains forward-looking statements regarding our strategy, future plans and prospects, including statements regarding the development of the company's product candidates pamrevlum
The New England Journal of Medicine (NEJM) publishes roxadustat CHINA PHASE 3 RESULTS for the TREATMENT OF anemia IN CHRONIC KIDNEY DISEASE patients receiving dialysis -- One of Two Concurrent Publications of Roxadustat China Phase 3 Results in The New England Journal of Medici
Read more →KYNBAbout Pamrevlumab Pamrevlumab is a first-in-class antibody developed by FibroGen to inhibit the activity of connective tissue growth factor (CTGF), a common factor in fibrotic and proliferative disorders characterized by
FibroGen Announces First Patient Dosed in ZEPHYRUS, a Phase 3 Clinical Trial of Pamrevlumab for the Treatment of Patients with Idiopathic Pulmonary Fibrosis SAN FRANCISCO, CA July 22, 2019 -- FibroGen, Inc. (NASDAQ: FGEN), today announced dosing of the first patient in the ZEPHY
Read more →KYNBPamrevlumab Mechanism of Action Overall Summary of Study FG-3019-079 in Non-Ambulatory Subjects with Duchenne Muscular Dystrophy Preliminary Clinical Results: Positive data that shows improvement over previously publishe
Study 079 - An Open-Label, Single-Arm Phase 2 Trial Evaluating Pamrevlumab, a Monoclonal Antibody to Connective Tissue Growth Factor (CTGF) in Non-Ambulatory Subjects with Duchenne Muscular Dystrophy (NCT02606136) PRELIMINARY CLINICAL RESULTS Ken Lipson, Ph.D. - Executive Directo
Read more →KYNBFIBROGEN
FIBROGEN APPOINTS SUZANNE BLAUG TO BOARD OF DIRECTORS SAN FRANCISCO, June 5, 2019 FibroGen, Inc. (NASDAQ: FGEN), a leading biopharmaceutical company discovering and developing a pipeline of first-in-class therapeutics, today announced the appointment of Suzanne Blaug as an indep
Read more →KYNBFIBROGEN REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS • Positive topline results from pooled safety analyses of roxadustat Phase 3 global program • Completed one year of treatment in Phase 2 trial evaluatin
FIBROGEN REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS Conference Call Today at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time SAN FRANCISCO, May 09, 2019 -- FibroGen, Inc. (NASDAQ: FGEN) today reported financial results for the first quarter of 2019 and provided an update on the
Read more →KYNBFIBROGEN REPORTS FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS --Roxadustat Approved in China for Anemia in Dialysis-Dependent CKD Patients- -Primary Efficacy Endpoints Met in Seven Phase 3 Roxadustat Studies for U
FIBROGEN REPORTS FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS --Roxadustat Approved in China for Anemia in Dialysis-Dependent CKD Patients- -Primary Efficacy Endpoints Met in Seven Phase 3 Roxadustat Studies for U.S./EU- -Conference Call Today at 5:00 p.m. Eastern Time/
Read more →KYNBFibroGen Announces Positive Topline Results from Three Global Phase 3 Trials of Roxadustat for Treatment of Anemia in Patients with Chronic Kidney Disease Primary efficacy endpoints met in all three studies: non-dialysis
FibroGen Announces Positive Topline Results from Three Global Phase 3 Trials of Roxadustat for Treatment of Anemia in Patients with Chronic Kidney Disease Primary efficacy endpoints met in all three studies: non-dialysis, incident dialysis, and stable dialysis studies SAN FRA
Read more →KYNBFibroGen Announces Approval of Roxadustat in China for the Treatment of Anemia in Chronic Kidney Disease Patients on Dialysis China is the First Country to Approve Roxadustat First-in-Class Roxadustat Offers a New, Effec
FibroGen Announces Approval of Roxadustat in China for the Treatment of Anemia in Chronic Kidney Disease Patients on Dialysis China is the First Country to Approve Roxadustat First-in-Class Roxadustat Offers a New, Effective Oral SAN FRANCISCO, December 17, 2018 FibroGen, Inc
Read more →KYNBFIBROGEN APPOINTS MAYKIN HO, PH.D.
FIBROGEN APPOINTS MAYKIN HO, PH.D., TO BOARD OF DIRECTORS SAN FRANCISCO, December 6, 2018 FibroGen, Inc. (NASDAQ: FGEN), a leading biopharmaceutical company discovering and developing a pipeline of first-in-class therapeutics, today announced the appointment of Maykin Ho, Ph.D.,
Read more →KYNBFIBROGEN REPORTS third QUARTER 2018 FINANCIAL RESULTS -Roxadustat New Drug Applications under Review in China and Japan- - Phase 3 Clinical Trials in IPF and Pancreatic Cancer to Initiate in First Quarter 2019- - Confere
FIBROGEN REPORTS third QUARTER 2018 FINANCIAL RESULTS -Roxadustat New Drug Applications under Review in China and Japan- - Phase 3 Clinical Trials in IPF and Pancreatic Cancer to Initiate in First Quarter 2019- - Conference Call Today at 5:00 p.m. Eastern Time/2:00 p.m. Pacifi
Read more →KYNBASN Kidney Week 2018: Data Presented from Two Japanese Phase 3 Studies on Roxadustat in the Treatment of Anemia Associated with Chronic Kidney Disease in Patients on Dialysis TOKYO and San Francisco
ASN Kidney Week 2018: Data Presented from Two Japanese Phase 3 Studies on Roxadustat in the Treatment of Anemia Associated with Chronic Kidney Disease in Patients on Dialysis TOKYO and San Francisco, October 30, 2018 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji
Read more →KYNBFibroGen Presents Results from Two Phase 3 Studies of Roxadustat for the Treatment of Anemia Associated with Chronic Kidney Disease Conducted in China at American Society of Nephrology Kidney Week 2018 Annual Meeting San
FibroGen Presents Results from Two Phase 3 Studies of Roxadustat for the Treatment of Anemia Associated with Chronic Kidney Disease Conducted in China at American Society of Nephrology Kidney Week 2018 Annual Meeting October 25, 2018 FibroGen, Inc. (NASDAQ: FGEN), a leading bio
Read more →KYNBAstellas Submits New Drug Application in Japan of Roxadustat for The Treatment of Anemia Associated with Chronic Kidney Disease in Patients on Dialysis TOKYO and San Francisco
Astellas Submits New Drug Application in Japan of Roxadustat for The Treatment of Anemia Associated with Chronic Kidney Disease in Patients on Dialysis TOKYO and San Francisco, October 1, 2018 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., Astell
Read more →KYNBAstellas Announces Positive Topline Results for Global Phase 3 Trial of Roxadustat in Chronic Kidney Disease (CKD) Patients with Anemia not on Dialysis TOKYO
Astellas Announces Positive Topline Results for Global Phase 3 Trial of Roxadustat in Chronic Kidney Disease (CKD) Patients with Anemia not TOKYO, September 20, 2018 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., Astellas ) today announced that rox
Read more →KYNBFIBROGEN REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS Roxadustat U.S. Phase 3 Topline Clinical Data Readout on Track for Fourth Quarter of 2018 Feedback from FDA on Pamrevlumab Pivotal Programs in IPF and in Locally Adv
FIBROGEN REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS Roxadustat U.S. Phase 3 Topline Clinical Data Readout on Track for Fourth Quarter of 2018 Feedback from FDA on Pamrevlumab Pivotal Programs in IPF and in Locally Advanced Unresectable Pancreatic Cancerr Conference Call To
Read more →KYNBMY (Michael Yee, Jefferies) TN (Thomas B. Neff, FibroGen) PY (K. Peony Yu, FibroGen) SP (Seth Porter, FibroGen) MY: Thank you for joining us for this afternoon session. Michael Yee, Managing Director and Senior Biotechno
MY (Michael Yee, Jefferies) TN (Thomas B. Neff, FibroGen) PY (K. Peony Yu, FibroGen) SP (Seth Porter, FibroGen) MY: Thank you for joining us for this afternoon session. Michael Yee, Managing Director and Senior Biotechnology Analyst here at Jefferies, and really happy to hav
Read more →KYNBFibroGen Announces Completion of Enrollment in U.S. Phase 3 Clinical Program for Roxadustat in Anemia Associated with Chronic Kidney Disease
FibroGen Announces Completion of Enrollment in U.S. Phase 3 Clinical Program for Roxadustat in Anemia Associated with Chronic Kidney Disease SAN FRANCISCO, Calif., June 7, 2018 FibroGen, Inc. (NASDAQ: FGEN), a biopharmaceutical company, today announced the completion of patient
Read more →KYNBFibroGen Presents Clinical Results of Pamrevlumab Treatment in Patients with Locally Advanced Unresectable Pancreatic Cancer at ASCO 2018 Annual Meeting Demonstrates Enhanced Rate of Surgical Resection with
FibroGen Presents Clinical Results of Pamrevlumab Treatment in Patients with Locally Advanced Unresectable Pancreatic Cancer at ASCO 2018 Annual Meeting Enhanced Rate of Surgical Resection with Pamrevlumab in Patients with Previously Unresectable Disease SAN FRANCISCO, Calif.,
Read more →KYNBAstellas and FibroGen Announce Topline Results from Double-Blind Japan Phase 3 Study for Roxadustat in Hemodialysis Chronic Kidney Disease Patients with Anemia TOKYO and San Francisco
Astellas and FibroGen Announce Topline Results from Double-Blind Japan Phase 3 Study for Roxadustat in Hemodialysis Chronic Kidney Disease Patients with Anemia Francisco, May 31, 2018 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., Astellas ) and
Read more →KYNBFIBROGEN PRESENTS LATEST DATA FROM PRAISE PHASE 2B STUDY OF PAMREVLUMAB IN IDIOPATHIC PULMONARY FIBROSIS AT AMERICAN THORACIC SOCIETY 2018 San Diego, CA
FIBROGEN PRESENTS LATEST DATA FROM PRAISE PHASE 2B STUDY OF PAMREVLUMAB IN IDIOPATHIC PULMONARY FIBROSIS AT AMERICAN THORACIC SOCIETY 2018 Diego, CA May 21, 2018 FibroGen, Inc. (NASDAQ: FGEN), a biopharmaceutical company, today announced that updated results from the company s
Read more →KYNBFIBROGEN REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS Pamrevlumab Data to be Presented at ATS 2018 and ASCO 2018 Roxadustat U.S. Phase 3 Clinical Studies on Track to Readout in Fourth Quarter 2018 Conference Call Today a
FIBROGEN REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS Pamrevlumab Data to be Presented at ATS 2018 and ASCO 2018 Roxadustat U.S. Phase 3 Clinical Studies on Track to Readout in Fourth Quarter 2018 Conference Call Today at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time SAN FRAN
Read more →KYNBFibroGen Reports Fourth QUARTER and FULL YEAR 2017 Financial Results Roxadustat U.S. Phase 3 Program in CKD Anemia Enrollment Completion and Data Readout in 2018 Pamrevlumab Phase 2 IPF Study Achieves Statistically Signi
FibroGen Reports Fourth QUARTER and FULL YEAR 2017 Financial Results Roxadustat U.S. Phase 3 Program in CKD Anemia Enrollment Completion and Data Readout in 2018 Pamrevlumab Phase 2 IPF Study Achieves Statistically Significant Attenuation of Lung Fibrosis as Measured by Quantit
Read more →KYNBThis presentation, the accompanying modules, and in each case the oral commentary contain "forward-looking" statements that involve substantial risks and uncertainties. All statements other than statements of historical
Corporate Presentation January 2018 This presentation, the accompanying modules, and in each case the oral commentary contain "forward-looking" statements that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in thi
Read more →KYNBFIBROGEN REPORTS THIRD QUARTER 2017 FINANCIAL RESULTS Roxadustat NDA Filing Accepted for CFDA Review; Positive Pamrevlumab Phase 2 IPF Results Reported Conference Call and Webcast to be Held Today at 5:00 p.m. Eastern Ti
FIBROGEN REPORTS THIRD QUARTER 2017 FINANCIAL RESULTS Roxadustat NDA Filing Accepted for CFDA Review; Positive Pamrevlumab Phase 2 IPF Results Reported Conference Call and Webcast to be Held Today at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time SAN FRANCISCO, November 8, 2017
Read more →KYNBAstellas and FibroGen Announce Positive Topline Results from First Japan Phase 3 Trial for Roxadustat in Chronic Kidney Disease Patients with Anemia Tokyo and San Francisco
Astellas and FibroGen Announce Positive Topline Results from First Japan Phase 3 Trial for Roxadustat in Chronic Kidney Disease Patients with Anemia and San Francisco, October 31, 2017 Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, Astellas ) and Fibro
Read more →KYNBFIBROGEN ANNOUNCES ACCEPTANCE BY CHINA FDA OF ROXADUSTAT NEW DRUG APPLICATION (NDA) FOR TREATMENT OF ANEMIA ASSOCIATED WITH DIALYSIS AND NON-DIALYSIS CHRONIC KIDNEY DISEASE (CKD) Triggers Milestone Payment o
FIBROGEN ANNOUNCES ACCEPTANCE BY CHINA FDA OF ROXADUSTAT NEW DRUG APPLICATION (NDA) FOR TREATMENT OF ANEMIA ASSOCIATED WITH DIALYSIS AND NON-DIALYSIS CHRONIC KIDNEY DISEASE (CKD) Triggers Milestone Payment of $15 Million by AstraZeneca SAN FRANCISCO, Oct. 18, 2017 FibroGen, I
Read more →KYNBFIBROGEN APPOINTS GERALD LEMA TO BOARD OF DIRECTORS San Francisco, CA
FIBROGEN APPOINTS GERALD LEMA TO BOARD OF DIRECTORS San Francisco, CA, September 19, 2017 FibroGen, Inc. (NASDAQ: FGEN), a science-based biopharmaceutical company, today announced that Gerald Lema, former President of Asia Pacific at Baxter International, has been appointed to
Read more →KYNBPRAISE Background Pamrevlumab (FG-3019) A Human MAb Targeting CTGF Preclinical Data Supportive of Reversal of the Process of Fibrosis1 Decline in lung density over 8 weeks of therapeutic administration in a mouse Radiati
The PRAISE Study A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Pamrevlumab (FG-3019) in Patients with Idiopathic Pulmonary Fibrosis Prof. Luca Richeldi, MD Policlinico A. Gemelli, Catholic University, Rome FIBROGEN STUDY#: F
Read more →KYNBcancer. Roxadustat, the company s most advanced product candidate, is an oral small molecule inhibitor of HIF prolyl hydroxylase activity in Phase 3 clinical development for the treatment of anemia in chronic kidney dise
FIBROGEN, INC. ANNOUNCES PRICING OF FOLLOW-ON OFFERING OF COMMON SAN FRANCISCO, Aug. 15, 2017 FibroGen, Inc. (NASDAQ:FGEN), a science-based biopharmaceutical company, today announced that it has priced an underwritten follow-on offering, which is expected to raise gross proceed
Read more →KYNBFIBROGEN REPORTS SECOND QUARTER 2017 FINANCIAL RESULTS Company Announces Positive Topline Results from Phase 2 Study in IPF Conference Call and Webcast to be Held Today at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time
FIBROGEN REPORTS SECOND QUARTER 2017 FINANCIAL RESULTS Company Announces Positive Topline Results from Phase 2 Study in IPF Conference Call and Webcast to be Held Today at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time SAN FRANCISCO, August 7, 2017 -- FibroGen, Inc. (NASDAQ: FG
Read more →KYNBQ2 2017 FibroGen Inc Earnings Call
Q2 2017 FibroGen Inc Earnings Call SAN FRANCISCO Aug 7, 2017 (Thomson StreetEvents) Preliminary Transcript of FibroGen Inc earnings conference call or presentation Monday, August 7, 2017 at 9:00:00pm GMT TEXT version of Transcript =============================================
Read more →KYNBFIBROGEN REPORTS FIRST QUARTER 2017 FINANCIAL RESULTS -Conference Call and Webcast to be Held Today at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time
FIBROGEN REPORTS FIRST QUARTER 2017 FINANCIAL RESULTS -Conference Call and Webcast to be Held Today at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time- SAN FRANCISCO, May 9, 2017 -- FibroGen, Inc. (NASDAQ: FGEN), a science-based biopharmaceutical company, today reported financial
Read more →KYNBFIBROGEN, INC. ANNOUNCES PRICING OF FOLLOW-ON
FIBROGEN, INC. ANNOUNCES PRICING OF FOLLOW-ON OFFERING OF COMMON STOCK SAN FRANCISCO, April 6, 2017 FibroGen, Inc. (NASDAQ:FGEN), a science-based biopharmaceutical company, today announced that the company has priced an underwritten follow-on offering, which is expected to rais
Read more →KYNBFIBROGEN ANNOUNCES CHINA FDA APPROVAL OF CTA TO CONDUCT PIVOTAL PHASE 2/3 CLINICAL TRIAL OF ROXADUSTAT IN ANEMIA ASSOCIATED WITH LOWER RISK MDS Expands Roxadustat Development Program Into Oncology-Related An
FIBROGEN ANNOUNCES CHINA FDA APPROVAL OF CTA TO CONDUCT PIVOTAL PHASE 2/3 CLINICAL TRIAL OF ROXADUSTAT IN ANEMIA ASSOCIATED WITH LOWER RISK MDS Expands Roxadustat Development Program Into Oncology-Related Anemia in China SAN FRANCISCO, March 31, 2017 FibroGen, Inc. (NASDAQ: FG
Read more →KYNBFIBROGEN REPORTS FISCAL 2016 FINANCIAL RESULTS -Conference Call and Webcast to be Held Today at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time
FIBROGEN REPORTS FISCAL 2016 FINANCIAL RESULTS -Conference Call and Webcast to be Held Today at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time- SAN FRANCISCO, March 1, 2017 -- FibroGen, Inc. (NASDAQ: FGEN), a science-based biopharmaceutical company, today reported financial resu
Read more →KYNBFibroGen s Roxadustat (FG-4592) Meets Primary Endpoints in Two Phase 3 Anemia Studies in China Roxadustat: effective in dialysis (hemodialysis and peritoneal dialysis) and non-dialysis chronic kidney disease (CKD) patien
FibroGen s Roxadustat (FG-4592) Meets Primary Endpoints in Two Phase 3 Anemia Studies in China Roxadustat: effective in dialysis (hemodialysis and peritoneal dialysis) and non-dialysis chronic kidney disease (CKD) patients SAN FRANCISCO - January 30, 2017 - FibroGen, Inc. (NAS
Read more →KYNBFibroGen Reports Financial Results for the Third Quarter of 2016 and Provides Corporate Update - Completes Enrollment of Roxadustat Phase 3 Studies in China for Anemia in CKD - - Conference Call and Webcast to be Held To
FibroGen Reports Financial Results for the Third Quarter of 2016 and Provides Corporate Update - Completes Enrollment of Roxadustat Phase 3 Studies in China for Anemia in CKD - - Conference Call and Webcast to be Held Today at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time-- SA
Read more →KYNBFibroGen Reports Financial Results for the Second Quarter of 2016 Enrollment Completed in Placebo-Controlled Study of FG-3019 (Pamrevlumab) in IPF China Phase 3 Top Line Data Expected by Year-End 2016 -Webcast Conference
FibroGen Reports Financial Results for the Second Quarter of 2016 Enrollment Completed in Placebo-Controlled Study of FG-3019 (Pamrevlumab) in IPF China Phase 3 Top Line Data Expected by Year-End 2016 -Webcast Conference Call Scheduled for 4:30pm EST Today- SAN FRANCISCO-Augu
Read more →KYNBAstellas and FibroGen Announce First Patient Treated in Phase 3 Studies and Positive Phase 2 Results of Roxadustat in Patients with Chronic Kidney Disease in Japan Tokyo and San Francisco
Astellas and FibroGen Announce First Patient Treated in Phase 3 Studies and Positive Phase 2 Results of Roxadustat in Patients with Chronic Kidney Disease in Japan Tokyo and San Francisco, July 25, 2016 Astellas Pharma Inc. (TSE:4503, Astellas ) and FibroGen, Inc. (Nasdaq: FGEN
Read more →KYNBFibroGen Announces Initiation by Astellas of Phase 3 Clinical Study in Japan of Roxadustat/ASP1517 for the Treatment of Anemia of Chronic Kidney Disease Triggering $10.0 Million Milestone Payment San Franci
FibroGen Announces Initiation by Astellas of Phase 3 Clinical Study in Japan of Roxadustat/ASP1517 for the Treatment of Anemia of Chronic Kidney Disease Triggering $10.0 Million Milestone Payment San Francisco June 9, 2016 FibroGen, Inc. (FibroGen), announced today that it wil
Read more →KYNBFibroGen Reports Financial Results for the First Quarter of 2016 Continued Progress in Roxadustat Phase 3 Studies; Promising Interim Pancreatic Cancer Data -Webcast Conference Call Scheduled for 4:30pm EST Today
FibroGen Reports Financial Results for the First Quarter of 2016 Continued Progress in Roxadustat Phase 3 Studies; Promising Interim Pancreatic Cancer Data -Webcast Conference Call Scheduled for 4:30pm EST Today- SAN FRANCISCO-May 9, 2016 -- FibroGen, Inc. (NASDAQ: FGEN) ("Fib
Read more →KYNBFibroGen Announces Fiscal 2015 Financial Results -- Webcast Conference Call Scheduled for 4:30pm EST Today
FibroGen Announces Fiscal 2015 Financial Results -- Webcast Conference Call Scheduled for 4:30pm EST Today - SAN FRANCISCO-February 29, 2016 -- FibroGen, Inc. (NASDAQ: FGEN) ("FibroGen"), a research-based biopharmaceutical company, today reported financial results for the year
Read more →Competitive Position
How KYNB ranks across every disease it competes inCompetitive Position is a premium feature
See how KYNB ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial